BioSpace News Archive

Impact NRS LLC (NRS), the National Institute for Biotechnology in the Negev (NIBN) and the Agricultural Research Organization (ARO) collectively announce the commencement of their partnership through the launch of RumenEra, Inc.

iZafe Group hereby announces that the partner Careium AB has signed an agreement with a municipality in Skåne, which has chosen to introduce the Swedish made medication robot Dosell in its operations.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda’s patent litigation against MSN regarding MSN’s Abbreviated New Drug Application seeking approval of its generic version of Vanda’s HETLIOZ® (tasimelteon).

Novan, Inc., announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

Xoran Technologies’ revolutionary, truly mobile 3D computed tomography imaging solution, vTRON™ has been selected by the North American Veterinary Community of industry veterinarians and veterinary technicians to be showcased in the New Product Gallery at the VMX Veterinary Meeting & Expo in Orlando, Florida, January 14-19, 2022.

Medlab Clinical Ltd (ASX:MDC) is pleased to announce in collaboration with Prof Pall Thordarson (Director of the UNSW RNA Institute, UNSW) and Prof Daniela Traini (NHMRC Investigator, Biomedical Sciences, Macquarie University and The Woolcock Institute of Medical Research) received a NSW Government grant to develop a Proof-of-Concept NanoCelle® Nasal RNA vaccine.

As of December 2021, Dr. Luciano Martelotto has joined the ambitious and AI-driven deep biotech start-up Omniscope as Chief Technology Officer, to support the company’s vision of bringing healthcare for everyone, everywhere.

2025 forecast: massive growth expected in consumer-friendly dosages using natural ingredients for proactive & pre-emptive health.

Technological advancements in alert systems, improving healthcare infrastructure, and rising preference towards personal health monitoring systems are some key factors expected to drive market growth.

Technological advancements in sequencing technologies, increasing application of spatial genomics and transcriptomics in biomarker identification and drug discovery, and increasing funding to expand R&D activities are key factors driving revenue growth of market.